INMED PHARMACEUTICALS INC. Payments to Acquire Short-term Investments
INMED PHARMACEUTICALS INC. (INM) reported Payments to Acquire Short-term Investments of $41.34 thousand for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. payments to acquire short-term investments for the quarter ending 2026-06-30 was -$327.00, a 114.66% decline year-over-year.
- INMED PHARMACEUTICALS INC. payments to acquire short-term investments for the quarter ending 2026-03-31 was $16.51K, a 2.96% increase year-over-year.
- INMED PHARMACEUTICALS INC. payments to acquire short-term investments for the quarter ending 2025-12-31 was $4.20K, a 56.80% increase year-over-year.
- INMED PHARMACEUTICALS INC. payments to acquire short-term investments for the quarter ending 2025-09-30 was $20.96K, a 1.72% decline year-over-year.
- INMED PHARMACEUTICALS INC. payments to acquire short-term investments for fiscal 2023 was $42.27K.
- INMED PHARMACEUTICALS INC. payments to acquire short-term investments for fiscal 2020 was $43.62K.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$327.00 derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $16.18K derived: sum of 2 quarters · filed 2026-09-09 | $20.38K derived: sum of 3 quarters · filed 2026-09-09 | $41.34K S-4/A · filed 2026-09-09 |
| 2026-03-31 | $16.51K derived: S-4 9 month − 10-Q 6 month · filed 2026-07-02 | $20.71K derived: sum of 2 quarters · filed 2026-07-02 | $41.67K S-4 · filed 2026-07-02 | $43.90K derived: sum of 4 quarters · filed 2026-09-09 |
| 2025-12-31 | $4.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | $25.16K 10-Q · filed 2026-02-11 | $27.39K derived: sum of 3 quarters · filed 2026-09-09 | $43.42K derived: sum of 4 quarters · filed 2026-09-09 |
| 2025-09-30 | $20.96K 10-Q · filed 2025-11-06 | $23.19K derived: sum of 2 quarters · filed 2026-09-09 | $39.23K derived: sum of 3 quarters · filed 2026-09-09 | $41.90K derived: sum of 4 quarters · filed 2026-09-09 |
| 2025-06-30 | $2.23K derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $18.27K derived: sum of 2 quarters · filed 2026-09-09 | $20.95K derived: sum of 3 quarters · filed 2026-09-09 | $42.27K S-4/A · filed 2026-09-09 |
| 2025-03-31 | $16.04K derived: S-4 9 month − 10-Q 6 month · filed 2026-07-02 | $18.71K derived: sum of 2 quarters · filed 2026-07-02 | $40.04K S-4 · filed 2026-07-02 | $39.61K derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-12-31 | $2.68K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | $24.00K 10-Q · filed 2026-02-11 | $23.57K derived: sum of 3 quarters · filed 2026-07-02 | $44.77K derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-09-30 | $21.32K 10-Q · filed 2025-11-06 | $20.89K derived: sum of 2 quarters · filed 2026-07-02 | $42.09K derived: sum of 3 quarters · filed 2026-07-02 | $42.09K derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-06-30 | -$431.00 derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | $20.77K derived: sum of 2 quarters · filed 2026-07-02 | $20.77K derived: sum of 3 quarters · filed 2026-07-02 | $42.08K S-4 · filed 2026-07-02 |
| 2024-03-31 | $21.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $21.20K derived: sum of 2 quarters · filed 2025-05-12 | $42.51K 10-Q · filed 2025-05-12 | |
| 2023-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | $21.32K 10-Q · filed 2025-02-12 | ||
| 2023-09-30 | $21.32K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $42.27K 10-K · filed 2024-09-30 | |||
| 2020-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-24 | $17.17K derived: sum of 2 quarters · filed 2021-09-24 | $17.56K derived: sum of 3 quarters · filed 2021-09-24 | $43.62K 10-K · filed 2021-09-24 |
| 2020-03-31 | $17.17K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-13 | $17.56K derived: sum of 2 quarters · filed 2021-05-13 | $43.62K 10-Q · filed 2021-05-13 | |
| 2019-12-31 | $382.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-11 | $26.45K 10-Q · filed 2021-02-11 | ||
| 2019-09-30 | $26.06K 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |